Key Points
- Teva CEO Richard Francis sold 442,935 shares on March 3 at an average price of $32.36 for a total of $14,333,376.60, reducing his direct stake by 40.82% to 642,099 shares.
- Teva beat expectations for the latest quarter with EPS of $0.96 (vs. $0.65 consensus) and revenue of $4.71B (vs. $4.36B), set FY2026 guidance of 2.570–2.770 EPS, and has a "Moderate Buy" analyst consensus with an average target of $37.67.
Teva Pharmaceutical Industries Ltd. (NYSE:TEVA - Get Free Report) CEO Richard Francis sold 442,935 shares of the company's stock in a transaction dated Tuesday, March 3rd. The stock was sold at an average price of $32.36, for a total transaction of $14,333,376.60. Following the completion of the sale, the chief executive officer directly owned 642,099 shares of the company's stock, valued at $20,778,323.64. The trade was a 40.82% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link.
Teva Pharmaceutical Industries Stock Performance
Shares of Teva Pharmaceutical Industries stock traded down $0.72 during mid-day trading on Friday, hitting $31.03. 1,740,747 shares of the stock were exchanged, compared to its average volume of 9,510,868. Teva Pharmaceutical Industries Ltd. has a 12 month low of $12.47 and a 12 month high of $37.35. The company has a 50-day simple moving average of $33.03 and a 200 day simple moving average of $26.11. The company has a market capitalization of $35.68 billion, a P/E ratio of 25.86, a P/E/G ratio of 11.02 and a beta of 0.72. The company has a debt-to-equity ratio of 1.89, a quick ratio of 0.80 and a current ratio of 1.04.
Teva Pharmaceutical Industries (NYSE:TEVA - Get Free Report) last released its earnings results on Wednesday, January 28th. The company reported $0.96 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.65 by $0.31. The company had revenue of $4.71 billion during the quarter, compared to analyst estimates of $4.36 billion. Teva Pharmaceutical Industries had a return on equity of 46.28% and a net margin of 8.16%.Teva Pharmaceutical Industries's quarterly revenue was up 11.4% on a year-over-year basis. During the same period in the prior year, the company posted $0.71 earnings per share. Teva Pharmaceutical Industries has set its FY 2026 guidance at 2.570-2.770 EPS. Sell-side analysts anticipate that Teva Pharmaceutical Industries Ltd. will post 2.5 earnings per share for the current fiscal year.
Analyst Ratings Changes
A number of analysts have issued reports on TEVA shares. Piper Sandler reissued an "overweight" rating and issued a $41.00 target price (up from $40.00) on shares of Teva Pharmaceutical Industries in a research report on Wednesday. Weiss Ratings reiterated a "sell (d-)" rating on shares of Teva Pharmaceutical Industries in a research report on Wednesday, January 21st. JPMorgan Chase & Co. increased their price target on shares of Teva Pharmaceutical Industries from $28.00 to $35.00 and gave the stock an "overweight" rating in a report on Tuesday, December 16th. The Goldman Sachs Group raised their price objective on shares of Teva Pharmaceutical Industries from $36.00 to $45.00 and gave the company a "buy" rating in a research report on Monday, February 9th. Finally, Scotiabank upped their target price on shares of Teva Pharmaceutical Industries from $35.00 to $40.00 and gave the stock a "sector outperform" rating in a report on Thursday, January 29th. One investment analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat, the stock has an average rating of "Moderate Buy" and an average target price of $37.67.
Read Our Latest Report on TEVA
Institutional Trading of Teva Pharmaceutical Industries
A number of large investors have recently modified their holdings of the business. Global Retirement Partners LLC grew its holdings in shares of Teva Pharmaceutical Industries by 27.3% during the fourth quarter. Global Retirement Partners LLC now owns 1,360 shares of the company's stock worth $42,000 after purchasing an additional 292 shares in the last quarter. Captrust Financial Advisors lifted its position in Teva Pharmaceutical Industries by 2.1% during the fourth quarter. Captrust Financial Advisors now owns 14,715 shares of the company's stock valued at $459,000 after purchasing an additional 302 shares during the last quarter. Banque Cantonale Vaudoise grew its stake in Teva Pharmaceutical Industries by 6.3% in the 4th quarter. Banque Cantonale Vaudoise now owns 5,133 shares of the company's stock worth $160,000 after buying an additional 306 shares in the last quarter. Ethic Inc. increased its holdings in shares of Teva Pharmaceutical Industries by 1.8% in the 4th quarter. Ethic Inc. now owns 18,127 shares of the company's stock worth $566,000 after buying an additional 325 shares during the last quarter. Finally, Allworth Financial LP increased its holdings in shares of Teva Pharmaceutical Industries by 53.8% in the 4th quarter. Allworth Financial LP now owns 941 shares of the company's stock worth $29,000 after buying an additional 329 shares during the last quarter. Institutional investors own 54.05% of the company's stock.
About Teva Pharmaceutical Industries
(
Get Free Report)
Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) is an Israeli multinational pharmaceutical company and one of the world's largest manufacturers of generic medicines. The company's core activities include the development, production and marketing of generic pharmaceuticals alongside a portfolio of specialty branded medicines. Teva supplies finished dosage forms and active pharmaceutical ingredients (APIs) to markets around the globe and operates manufacturing and research facilities in multiple countries.
Teva's product range covers oral solids, injectables, inhalation products and other dosage forms across therapeutic areas such as central nervous system disorders, respiratory, oncology, pain and infectious disease.
Further Reading
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
